文献速递乳腺癌

HER2阳性早期乳腺癌降阶梯策略:WSG-ADAPT HER2+/HR-二期最终分析

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
PubMed 文献 · Ann Oncol · 2017-01-01

WSG-ADAPT HER2+/HR-二期试验纳入HER2阳性/激素受体阴性早期乳腺癌女性,随机(5:2)接受12周曲妥珠单抗+帕妥珠单抗±每周紫杉醇80 mg/m2。双靶+化疗组pCR率90.5%,双靶单药组整体36.3%;双靶单药组中早期应答者pCR率44.7%,非应答者仅8.3%。

要点

  • 双靶+紫杉醇组pCR率90.5%,双靶单药组整体36.3%。
  • 双靶单药组早期应答者pCR率44.7%,非应答者仅8.3%。
  • 双靶单药组未分类早期应答者pCR率为42.9%。

核心结论

  • 在12周新辅助治疗中,双HER2阻断基础上加用紫杉醇单药较双靶单药显著提高HER2+/HR-早期乳腺癌的pCR率,即使在双靶治疗早期应答者中亦然。
  • 双靶治疗下早期非应答强烈预测无法达到pCR。

研究设计与样本

  • 前瞻性、二期、新辅助WSG-ADAPT HER2+/HR-试验,纳入HER2+/HR-早期乳腺癌(M0)女性患者,随机(5:2)接受12周曲妥珠单抗+帕妥珠单抗±每周紫杉醇80 mg/m2。
  • 2014年2月至2015年12月筛查160例,随机分配92例至T+P组、42例至T+P+pac组。
  • 早期应答定义为3周活检中Ki-67较基线下降≥30%或细胞密度低(<500个浸润性肿瘤细胞)。
  • 试验设计为检验T+P组早期应答患者pCR非劣效于所有接受化疗的患者。

主要发现

  • T+P+pac组pCR率为90.5%,T+P组整体pCR率为36.3%。
  • T+P组中24/92例为非应答者,其pCR率为8.3%;应答者(38/92例)pCR率为44.7%,早期应答未分类者(30/92例)pCR率为42.9%。
  • T+P组91.3%的患者按方案完成治疗,T+P+pac组为92.9%。
  • 研究人群中未观察到新的安全性信号。
  • 基线特征均衡:中位年龄T+P组54岁 vs T+P+pac组51.5岁;cT2分别为51.1% vs 52.4%;cN0分别为54.3% vs 61.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Response rates in HER2-overexpressing EBC treated with neoadjuvant chemotherapy and trastuzumab (T) have been improved by addition of pertuzumab (P). The prospective, phase II, neoadjuvant WSG-ADAPT HER2+/HR- trial assessed whether patients with strong early response to dual blockade alone might achieve pathological complete response (pCR) comparable to that of patients receiving dual blockade and chemotherapy. PATIENTS AND METHODS: Female patients with HER2+/HR- EBC (M0) were randomized (5:2) to 12 weeks of T + P ± weekly paclitaxel (pac) at 80 mg/m2. Early response was defined as proliferation decrease ≥30% of Ki-67 (versus baseline) or low cellularity (<500 invasive tumor cells) in the 3-week biopsy. The trial was designed to test non-inferiority for pCR in early responding patients of the T + P arm versus all chemotherapy-treated patients. RESULTS: From February 2014 to December 2015, 160 patients were screened, 92 were randomized to T + P and 42 to T + P+pac. Baseline characteristics were well balanced (median age 54 versus 51.5 years, cT2 51.1 versus 52.4%, cN0 54.3 versus 61.9%); 91.3% of patients completed T + P per protocol and 92.9% T + P+pac. The pCR rate in the T + P+pac arm was 90.5%, compared with 36.3% in the T + P arm as a whole. In the T + P arm, 24/92 were classified as non-responders, and their pCR rate was only 8.3% compared with 44.7% in responders (38/92) and 42.9% in patients with unclassified early response (30/92). No new safety signals were observed in the study population. CONCLUSION: Addition of taxane monotherapy to dual HER2 blockade in a 12-week neoadjuvant setting substantially increases pCR rates in HER2+/HR- EBC compared with dual blockade alone, even within early responders to dual blockade. Early non-response under dual blockade strongly predicts failure to achieve pCR.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Ann Oncol. 2017. PMID: 28945833. doi:10.1093/annonc/mdx494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。